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Abstract
The influence of antipsychotic treatment on the neuro-
psychological and psychomotor performance of schizo-
phrenic patients is still a subject of investigation. The
present study was designed to evaluate the effects of
atypical neuroleptics in comparison with a conventional
dopamine antagonist neuroleptic (haloperidol) on sever-
al dimensions of psychomotor performance (visual per-
ception, attention, reaction time, and sensorimotor per-
formance) considered to be of relevance in evaluating
driving fitness. Psychomotor performance was assessed
by means of the ART 90, a computerized Act and React
Test which is generally used in diagnosis of psychomo-
tor performance. The 49 participating patients were ex-
amined at discharge following psychopathological sta-
bilisation; 20 received haloperidol, 29 received an atypi-
cal neuroleptic. Our findings demonstrate a remarkably
reduced psychomotor performance in the haloperidol-
treated group of schizophrenic patients compared with
patients treated with atypical neuroleptics. Only 1 (5%)
subject passed all subtests without major failures and
could be regarded as competent to drive. Among pa-
tients with atypical neuroleptics, 7 patients (24%) passed
all test parameters without major failures.
Copyright © 2003 S. Karger AG, Basel
Introduction
Cognitive dysfunction in schizophrenia is common
and has already been described by Kraepelin [1]. It is a
key symptom in schizophrenia and is seen early in the
development of the disorder. It is initially mild, but often
increases in severity in chronic patients. Impaired cogni-
tive function in schizophrenia is recognized as a pervasive
deficit, which is independent of positive symptoms and
often persists after reduction of psychotic symptoms. It is
not restricted to any subgroup of patients and is seen in
variable intensity among almost all schizophrenic pa-
tients [2]. However, it is difficult to distinguish syndrome-
related dysfunction from cognitive impairment resulting
from the side-effects of antipsychotic medications. Clini-
cal data suggest that treatment with novel antipsychotic
medications like risperidone, clozapine or amisulpride
may have a positive effect on impaired cognition and psy-
chomotor performance [3–6].
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The present study was designed to compare schizo-
phrenic patients receiving an atypical neuroleptic with
patients receiving a conventional dopamine antagonist
neuroleptic (haloperidol) in relation to psychomotor per-
formance. We used several psychomotor tests developed
by the Austrian road safety board for the examination of
car, bus, and taxi drivers in accordance with German
guidelines for road and traffic safety [7]. However, driv-
ing ability is not only a matter of psychomotor perfor-
mance. An individual’s driving experience, coping strate-
gies for deficits and compliance, which are not a subject of
this study, must also be considered. Improvement in cog-
nitive functioning leads to improved skills in social prob-
lem-solving, improved psychosocial skills and improved
quality of life [8]. Driving fitness can be regarded as an
important factor of social functioning and may be of
importance for compliance with treatment.
There are few studies of schizophrenic patients which
investigate the influence of antipsychotic medication on
neuropsychological and psychomotor performance, espe-
cially on driving ability. Laux [9] and Grabe et al. [10]
found that only 10% of neuroleptic-treated patients
showed no impairment in fitness to drive during the last 2
weeks of their hospitalisation. The findings of Grabe et al.
[10] indicate that clozapine-treated patients compared
with patients treated with different classic neuroleptics
performed better on a test measuring resistance to stress
and the capacity to integrate information. However, only
10% of the patients in each group successfully passed eve-
ry test in the test battery.
Subjects and Methods
We conducted a naturalistic, non-randomised, clinical study at
the Psychiatric Hospital of the University of Munich, Munich, Ger-
many, with 49 (28 male, 21 female) patients who met the ICD-10 and
DSM-IV criteria for schizophrenia or a schizoaffective disorder.
Study patients were clinically stabilized, had a steady state of neuro-
leptic medication and were ready for discharge. Of the 29 patients
(15 male, 14 female) treated with atypical neuroleptics, 5 received
clozapine, 4 received amisupride, 7 received riperidone, 8 received
quetiapine, 4 received olanzapine and 1 received ziprasidone, all in
different dosages. The 20 patients (13 male, 7 female) treated with
haloperidol received a dosage of 4–30 mg/day. Although a monother-
apy was favoured, 7 received an additional medication when clinical-
ly indicated. There was no significant difference in age, sex, educa-
tion and Brief Psychiatric Rating Scale (BPRS) scores between the
haloperidol-treated group and the group treated with atypical neuro-
leptics. Patients were excluded if they had a disabling physical disor-
der, organic brain disorder, acute substance abuse, or any serious
concurrent medical condition. There was no evidence of extrapyram-
idal-motoric symptoms in any of the study patients. All patients had
either a valid driver’s licence or intended to obtain one within the
next few months. All subjects participated voluntarily in the study
and gave their informed consent. A description of the sample is pre-
sented in table 1.
Relevant psychomotor skills for driving fitness where assessed by
the Act and React Test system (ART 90), a standardized and com-
puterized test unit developed by the Austrian road safety board (Ku-
ratorium für Verkehrssicherheit, Vienna, Austria). The reliability
and validity of this test battery have been confirmed in large samples
of both community and clinical subjects. In several driving experi-
ments, the tests have been found to predict driving performance
under different traffic situations [11, 12]. The computerized tests of
the ART system are often used in the evaluation of psychomotor per-
formance in psychological examinations.
Tests measuring peripheral vision, divided attention, sensorimo-
tor function, reaction time, stress resistance and the capacity to inte-
grate information were used to assess psychomotor performance in
relation to driving fitness. These tasks were selected as they are part
of the driving examinations in Germany and had been used in pre-
vious studies investigating driving fitness [10, 13].
Peripheral Vision Test with Tracking Task
The Peripheral Vision Test (PVT) with tracking task assesses
peripheral visual perception, divided attention, sensorimotor perfor-
mance and reaction time. The subject is required to react to light
patterns which randomly move from the left or right periphery into
his/her visual field while performing a tracking test that is displayed
in front of him/her.
Tachistoscope Test
The Tachistoscope Test (TT15) was designed to measure the abil-
ity to quickly extract relevant information from typical traffic situa-
tions presented for 0.75 s. The subject has to answer 3 multiple-
choice questions for each slide.
Reactive Stress Tolerance Test
The Reactive Stress Tolerance Test (RST3) requires a high level
of concentration to visual and acoustic stimuli and tolerance to high
stress in order to integrate information and to be able to react to each
stimulus in the defined way. The subject is asked to press buttons,
bars and pedals corresponding to presented colours, tones and light
stimuli. The RST3 has 3 test phases with different presentation rates,
i.e. phase 1: 38 signs/min; phase 2: 63 signs/min, and phase 3: 56
signs/min. The results of phase 2 with the highest speed of the pre-
sented stimuli are used as an indicator of stress resistance and the
capacity to integrate information.
Attention Test
The attention test (Q1) examines attention under a monotonous
condition. The subject has to identify as ‘different’ or ‘identical’ 4
figures that are presented constantly in 4 displays with another figure
in a fifth display. The test is time dependent.
The computerized test system evaluates the subjects’ test perfor-
mance in comparison with the population norms. The test adminis-
trator is able to determine if the performance of the tested person
exceeds the defined threshold of 15%, i.e., 1 SD below the mean of
the population norm. As there are no general standards for success-
ful test performance, the test administrator decides whether the per-
son is able to compensate for deficits in individual test perfor-
mance; however, test performance deficits are not cumulative
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Table 1. Sample characteristics of the two groups
Atypical neuroleptics
(n = 29)
Haloperidol
(n = 20)
Mean age, years 30.3 (19–49) 33.1 (19–49)
Sex (M/F) 15/14 13/7
Mean medication dosage, mg 4 patients: amisulpride 625 (400–1,000)
5 patients: clozapine 285 (125–450)
8 patients: quetiapine 744 (200–1,200)
7 patients: risperidone 5 (3–10)
4 patients: olanzapine 21.25 (20–25)
1 patient: ziprasidone 80
7.3 (4–30)
Hospitalization, weeks 9.7 5.7
ICD-10 diagnosis
F 20.0 21 12
F 20.1 4 2
F 20.2 1 2
F 23.2 1 4
F 25.1 2 0
Mean BPRS scores at examination 26.3 27.0
Mean level of education (9–18 years)1 3.3 3.4
Figures in parentheses indicate ranges.
1 On a scale from 1 to 5.
across the battery. The more test scores fall 1 SD below the mean,
the less likely the person is able to compensate deficits. If a person’s
score falls below the threshold on more than 4 test parameters, he/
she was rated as unable to compensate for his/her deficits and unfit
to drive.
Statistical data analysis was performed using SPSS (Statistical
Package for Social Science, Version 11.0, Chicago, SPSS Inc., 2002).
Non-parametric tests were conducted, since the test scores were not
normally distributed. The Mann-Whitney U test was used to deter-
mine between-group differences, and Spearman correlations were
computed to determine the relation between neurocognitive test
results and education, duration of stay at the hospital, and BPRS
scores. As an index of effect size, the mean of between-group differ-
ences was used.
Results
First, the overall psychomotor performance of subjects
was examined to determine their driving ability in rela-
tion to the German regulations of road safety. For each of
the 4 tests, the subjects’ performance was indicated by
multiple scores. The raw score data were compared with
the performance of large samples of normal controls. A
test is considered as ‘passed’ if the patient exceeds the
threshold of 15% with respect to each unit of the test (16%
Fig. 1. Psychomotor test performance of patients treated with atypi-
cal neuroleptics vs. haloperidol. Passed = All tests; low perfor-
mance = failed 1–4 test parameters; very low performance = failed
14 test parameters.
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Table 2. Test performance of both groups
Test Atypical
neuroleptics,
mean B SD
(n = 29)
Haloperidol
mean B SD
(n = 20)
Effect
size
z p
PVT
Reaction time, total s 1.8B0.8 1.8B0.9 0 –0.432 0.666
Tracking performance, mean deviation in total 4.1B2.0 4.9B1.8 0.8 –2.238 0.025*
TT15
Correct answers 29.1B4.9 30.1B4.5 1 –0.384 0.701
Mean reaction time, min 4.4B1.6 3.4B0.8 1 –2.712 0.007*
Q1
Completed trials 407.0B106.7 381.7B85.5 25.3 –0.706 0.480
Incorrect responses, % 4.3B4.9 4.5B4.5 0.2 –0.591 0.591
RST3 (Phase 1)
Correct responses 165.5B20.0 156.3B28.5 9.2 –1.570 0.116
Correct answers on time 152.2B32.1 138.6B34.9 13.6 –1.993 0.046*
Delayed responses 13.4B14.6 17.8B11.8 4.4 –1.786 0.074
Delayed compared with correct responses, % 9.1B11.4 12.4B9.3 3.3 –1.904 0.057
Omissions 10.2B15.0 19.8B25.8 9.6 –1.654 0.098
Incorrect responses 4.2B6.5 3.9B4.2 0.3 –0.792 0.428
Incorrect compared with total responses, % 5.3B6.4 7.7B10.3 2.4 –1.358 0.174
Multiple responses 4.9B5.8 9.6B19.3 4.7 –0.861 0.389
RST3 (Phase 2)
Correct responses 134.2B37.6 106.8B26.2 27.4 –2.504 0.012*
Correct answers on time 70.7B50.3 39.0B43.6 31.7 –2.056 0.040*
Delayed responses 62.0B23.9 70.33B23.8 8.3 –1.147 0.251
Delayed compared with correct responses, % 53.1B26.4 69.2B24.7 16.1 –1.894 0.058
Omissions 39.8B32.7 60.7B26.7 20.9 –1.870 0.061
Incorrect responses 6.3B6.8 9.9B9.4 3.6 –1.552 0.121
Incorrect compared with total responses, % 10.8B10.3 15.0B12.2 4.2 –1.387 0.166
Multiple responses 8.2B8.0 9.4B11.0 1.2 –0.025 0.980
RST3 (Phase 3)
Correct responses 148.4B32.9 131.3B30.4 17.1 –1.784 0.074
Correct answers on time 102.3B53.3 70.6B40.6 31.7 –1.820 0.069
Delayed responses 46.0B27.2 60.9B28.4 14.9 –1.709 0.087
Delayed compared with correct responses, % 35.7B26.0 48.4B21.9 12.7 –1.721 0.085
Omissions 26.2B28.2 40.7B26.4 14.5 –1.883 0.060
Incorrect responses 5.4B6.8 7.7B6.7 2.3 –1.595 0.111
Incorrect compared with total responses, % 8.4B10.2 12.3B12.3 3.9 –1.510 0.131
Multiple responses 7.2B9.8 10.7B15.0 7.2 1.092 0.275
* p ! 0.05.
reflects 1 SD below the mean score of normal controls).
Adequate driving ability is indicated if the subject ex-
ceeds the threshold of 15% in each unit of the 4 tests.
Among patients treated with atypical neuroleptics, 7
persons out of 25 (24%) passed each unit of the 4 tests
which means exceeding the 15% guideline (fig. 1) regard-
ing fitness to drive. Of these 7 patients, 2 received cloza-
pine, 1 received amisulpride (along with biperiden and
benzodiazepine), 1 received olanzapine, 1 received risper-
idone (along with biperiden) and 2 received quetiapine.
Of the haloperidol-treated patients, only 1 person (5%)
passed all tests without any failures.
According to the German driving examination guide-
lines, low driver performance on some test parameters is
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
7/
29
/2
01
3 
1:
08
:5
6 
PM
216 Neuropsychobiology 2003;47:212–218 Kagerer/Winter/Möller/Soyka
allowed, if the results on other tests are satisfactory; an
accumulation of test deficits across the examination is
excluded. In these cases, pass/fail is determined by the test
administrator. Eleven patients (38%) treated with atypi-
cal neuroleptics showed a low performance on 1–4 test
scores, while 5 patients (25%) in the haloperidol-treated
group failed the threshold of 15% on 1–4 test scores. For
these patients, further examinations were recommended.
Poor test performance on more than 4 test parameters
(i.e., very low performance) was found for 14 patients
(70%) treated with haloperidol and 11 patients (38%)
treated with atypicals. These patients, in our opinion,
were not able to compensate for their psychomotor defi-
cits and were classified as unfit for driving. Three of the
haloperidol-treated patients were not able to complete all
of the tests and testing was stopped. In the statistical anal-
ysis comparing the two groups (table 2), their data were
considered as ‘missing’. For the analysis, they were rated
as ‘failed’ on the relevant test parameters. One person
misunderstood the test instructions of 1 test, while 3 sub-
jects refused to complete all 4 tests. A tendency of an asso-
ciation between grouping variables (haloperidol vs. atypi-
cals) and classification (‘passed’, ‘low performance’, ‘very
low performance’) was observed (Pearson’s ¯2 test 5.647,
d.f. = 2, p = 0.058).
Next, the two groups were compared without using a
threshold definition considering each test score of the 4
tests (table 2). On the PVT, a significant between-group
difference was found on 1 item of the test. Patients treated
with the atypical neuroleptics showed a significantly bet-
ter psychomotor performance on the tracking task; no
between-group differences were found on reaction time in
this test. On the TT15, the haloperidol-treated group
showed a significantly shorter reaction time. No differ-
ences were found in the number of correct response items.
On the Q1, no significant between-group differences were
found. On the RST3, a test measuring stress resistance
and the capacity to integrate information, the patients
treated with atypical neuroleptics showed a better perfor-
mance on all dimensions. In phase 1 of the test, patients
treated with atypical neuroleptics performed significantly
better on time responses. In phase 2, the ‘highest stress
level’, patients treated with atypical neuroleptics pro-
vided significantly more correct responses and more cor-
rect responses in time allowed, a tendency of a less per-
centage of delayed responses (p = 0.058) and less omis-
sions (p = 0.061) than the haloperidol-treated subjects. In
phase 3 of the RST3, a tendency of a better performance
of the group treated with atypical neuroleptics was seen
across all dimensions. They provided more correct an-
swers (p = 0.074), more correct answers in time allowed
(p = 0.069), less delayed responses (p = 0.085) and less
omissions (p = 0.060) than the haloperidol-treated pa-
tients.
Furthermore, a correlation analysis was conducted to
examine the relationship between psychomotor test per-
formance and age, BPRS score, educational level, and the
duration of stay at the hospital.
No association was found between psychomotor test
results and education or duration of stay at the hospital.
However, there was a significant, but low correlation
between age and correct answers in phase 2 of the RST3
(Ú = –0.325), correct answers on time in the second (Ú =
–0.414) and third phase of the RST3 (Ú = –0.351), and
delayed responses in phase 2 (Ú = 0.379) and phase 3 (Ú =
0.398). Similarly, a significant, but low correlation be-
tween age and the tracking performance on the PVT test
(Ú = 0.397) was observed. Younger patients showed a bet-
ter test performance than older patients did. The BPRS
score was significantly correlated with only 2 items of the
RST3 (number of omissions in phase 1, Ú = 0.307 and
percentage of omissions in phase 1, Ú = 0.307).
Discussion
Functional status including psychomotor skills and
driving ability is of great importance for the rehabilitation
of schizophrenic patients. Palmer et al. [14] reported that
43% of middle-aged and elderly out-patients with schizo-
phrenia are currently drivers. The role of different neuro-
leptics in affecting neuropsychological abilities is of great
relevance in this respect, a relationship which only few
studies have examined to date.
Schizophrenic patients treated with different atypical
neuroleptics were compared with those treated with halo-
peridol in relation to their psychomotor functioning,
including driving fitness. Patients were examined at dis-
charge following neuroleptic treatment and psychopatho-
logical stabilisation – a clinical situation in which the
question of driving ability is of relevance.
The main result of our study is that the group of halo-
peridol-treated patients showed considerable psychomo-
tor impairment compared with patients who received an
atypical neuroleptic medication.
The significantly better results in some parameters of
the RST3 indicating a better stress tolerance among the
patients treated with atypical neuroleptics support the
findings of other published studies indicating a positive
effect of atypical neuroleptics on cognition [13, 15–17].
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Grabe et al. [10], also observed a better psychomotor test
performance of clozapine-treated patients compared with
patients treated with perazine, flupentixol, haloperidol,
chlorprothixene and amisulpride on the RST3. However,
they found no differences between both groups in terms of
the number of individuals who passed all tests without
failures. Similarly, Gallhofer et al. [4] found that risperi-
done and clozapine may have a positive effect on cogni-
tion compared with haloperidol in schizophrenic patients.
Hagger et al. [18] and Buchanan et al. [19] reported a sig-
nificant improvement in neuropsychological performance
during clozapine treatment in schizophrenic patients.
Purdon et al. [20] found that olanzapine produced a sub-
stantial gain in cognitive skills greater than that observed
with risperidone or haloperidol. Sax et al. [21] reported a
significant improvement during treatment with quetia-
pine in attentional functioning in patients with schizo-
phrenia. However, Classen and Laux [22] did not find
major differences in sensorimotor performance compar-
ing schizophrenic patients treated with haloperidol, flu-
pentixol and clozapine.
Since this study was conducted in a clinical setting, cer-
tain study limitations in relation to subject selection must
be discussed. First, a certain selection of patients must be
noted. Only patients with clear psychopathological im-
provement, free of relevant other medical disorders were
able to participate. Since the entire experimental proce-
dure lasted 90 min, on average, severely disturbed pa-
tients had to be excluded. The ability to drive must be
excluded as part of their clinical condition. Second, the
study followed a naturalistic approach. The sample re-
ceived different types and dosages of medication, and
some patients received additional medications as clinical-
ly indicated. Group differences in duration of illness,
individual motivation, in psychopathology and addition-
al symptoms (like mood or sleep disturbance) may be
present.
According to our findings, even after selection of com-
paratively well-stabilized patients, severe impairment of
psychomotor performance can be noticed. A careful eval-
uation of the driving abilities of schizophrenic patients is
recommended, as there can be considerable individual
differences between patients. Even though driving ability
was judged by using the ART-90, a very reliable and
objective method, a linear association between a person’s
test results and driving ability is not absolutely warranted.
Other important variables such as driving experience,
personality traits, duration and course of the illness
(which were not part of our investigation) are of rele-
vance. In addition, it must be emphasized that patients
should be informed about the danger of the combination
of antipsychotic medication and alcohol. Vollrath and
Krüger [23] reported an exponentially increased risk of an
accident if psychotropic substances like benzodiazepines
or cannabis are combined with alcohol.
To verify our findings, additional prospective, ran-
domised studies with larger samples should be conducted.
Medication, dosing issues, the possible influences of other
medications, psychopathological symptoms and the dura-
tion of illness should be considered to address the impor-
tant issue of medication effects on neuropsychological
functioning among schizophrenic patients.
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